Triple negative breast cancer, often called TNBC, is defined by the absence of three common treatment targets: estrogen receptors, progesterone receptors, and HER2 overexpression. This means that hormone therapies and HER2 targeted medicines used for some other breast cancer types are generally not suitable. However, several treatment approaches may be used depending on whether the cancer is early stage, locally advanced, or metastatic.
Understanding Treatment Options for Triple Negative Breast Cancer
Treatment for early stage TNBC commonly involves a combination of systemic therapy and local treatment. The order and selection of treatment can depend on tumor size, lymph node involvement, overall health, and other clinical factors.
- Chemotherapy: Chemotherapy is commonly used because TNBC can respond to medicines that destroy or slow the growth of rapidly dividing cancer cells. It may be given before surgery, known as neoadjuvant chemotherapy, or after surgery as adjuvant treatment.
- Surgery: Depending on the cancer and individual circumstances, surgery may involve breast conserving surgery or removal of the breast. Lymph nodes may also be evaluated to determine whether cancer cells have spread.
- Radiation therapy: Radiation may be recommended after surgery in certain situations. It uses high energy radiation to target remaining cancer cells in a specific area and may help reduce the risk of local recurrence.
- Immunotherapy: Some people with TNBC may receive immunotherapy in combination with chemotherapy. Eligibility depends on factors such as the stage of cancer, treatment setting, and specific characteristics of the tumor.
Advanced and Personalized Approaches to TNBC Treatment
For metastatic or recurrent TNBC, treatment may involve additional approaches based on the biological features of the cancer. Testing the tumor can provide information that helps healthcare professionals determine whether particular medicines may be appropriate.
- Targeted therapies: Certain targeted medicines may be considered when specific genetic changes or other biomarkers are identified. For example, some treatment approaches may be relevant for people with inherited BRCA mutations or other qualifying tumor characteristics.
- Antibody drug conjugates: These medicines are designed to deliver anti cancer treatment more directly to cells carrying a particular target. Their use depends on the type and stage of cancer and previous treatments.
- Clinical trials: Clinical research may provide access to investigational treatments while also helping researchers study new approaches for TNBC management.
- Ongoing monitoring: Follow up care may include physical examinations, discussions about symptoms, management of treatment side effects, and additional tests when clinically appropriate.
Triple negative breast cancer treatment is individualized rather than based on a single approach. A healthcare team may consider the cancer stage, tumor characteristics, genetic findings, previous treatments, and the person's overall health when developing a treatment plan. Discussing available options and potential benefits and risks with qualified healthcare professionals can support informed treatment decisions. This information is intended for educational purposes only and does not provide medical, sales, or treatment services.